Nettore Immacolata Cristina, Fenzi Gianfranco, Macchia Paolo E
Università degli Studi di Napoli “Federico II”, Dipartimento di Medicina Cinica e Chirurgia, Via S. Pansini, 5. 80131 Napoli – ITALY
Professor of Medicine Universit
Congenital hypothyroidism (CH) is the most frequent endocrine-metabolic disease in infancy, with an incidence of about 1/2500 newborns [1, 2]. In the last 20-30 years the incidence of congenital hypothyroidism in newborns has increased from 1:4000 to 1:2000 [3, 4]. This phenomenon could be explained by using a lower b-TSH cutoff, that allowed the detection of an unsuspected number of children with neonatal hypothyroidism [5]. With the exception of rare cases due to hypothalamic or pituitary defects, CH is characterized by elevated TSH in response to reduced thyroid hormone levels. In absence of an adequate treatment, CH determines growth retardation, delays in motor development, and permanent intellectual disability. Primary CH is determined by alterations occurring during the thyroid gland development (thyroid dysgenesis, TD [6]) or alterations in the thyroid hormone biosynthesis pathways (thyroid dyshormonogenesis). Less common causes of CH are secondary or peripheral defects in TSH synthesis and/or action, defects in thyroid hormone transport, metabolism, or action [7]. Table 1 shows a summary of the forms of CH with a genetic cause. In the majority of cases (80-85%), primary permanent CH is associated with TD. These forms include developmental disorders such as athyreosis, ectopy, hemiagenesis or hypoplasia. TD occurs mostly as sporadic disease, however a genetic cause has been demonstrated in about 2-5% of the reported cases [8]. Genes associated with TD include several thyroid transcription factors expressed in the early phases of thyroid organogenesis (, , , ) as well as genes, like the thyrotropin receptor gene () expressed later during gland morphogenesis. In the remaining 15-20% of cases, CH is caused by inborn errors in the molecular steps required for the biosynthesis of thyroid hormones, and generally it is characterized by enlargement of the gland (goiter), presumably due to elevated TSH levels [9]. Generally, thyroid dyshormonogenesis shows classical Mendelian recessive inheritance. Rarely CH has a central origin, as consequence of hypothalamic and/or pituitary diseases, with reduced production or function of thyrotropin releasing hormone (TRH) or thyrotropin hormone (TSH) [10]. For complete coverage of this and all related areas of Endocrinology, please visit our FREE on-line web-textbook, www.endotext.org.
先天性甲状腺功能减退症(CH)是婴儿期最常见的内分泌代谢疾病,发病率约为1/2500新生儿[1,2]。在过去20 - 30年中,新生儿先天性甲状腺功能减退症的发病率已从1:4000增至1:2000[3,4]。这种现象可以用较低的促甲状腺激素(b - TSH)临界值来解释,该临界值使得能够检测出数量不明的新生儿甲状腺功能减退症患儿[5]。除了极少数由下丘脑或垂体缺陷引起的病例外,CH的特征是甲状腺激素水平降低时促甲状腺激素升高。若未得到适当治疗,CH会导致生长发育迟缓、运动发育延迟和永久性智力残疾。原发性CH是由甲状腺发育过程中发生的改变(甲状腺发育异常,TD[6])或甲状腺激素生物合成途径中的改变(甲状腺激素合成障碍)所致。CH较罕见的病因是促甲状腺激素合成和/或作用的继发性或外周性缺陷、甲状腺激素转运、代谢或作用方面的缺陷[7]。表1总结了具有遗传病因的CH类型。在大多数病例(80 - 85%)中,原发性永久性CH与TD相关。这些类型包括发育障碍,如甲状腺缺如、异位、半侧发育不全或发育不良。TD大多为散发性疾病,然而在约2 - 5%的报告病例中已证实存在遗传病因[8]。与TD相关的基因包括在甲状腺器官发生早期表达的几种甲状腺转录因子( , , , )以及在腺体形态发生后期表达的基因,如促甲状腺激素受体基因( )。在其余15 - 20%的病例中,CH是由甲状腺激素生物合成所需分子步骤中的先天性缺陷引起的,通常其特征是甲状腺肿大(甲状腺肿),可能是由于促甲状腺激素水平升高所致[9]。一般来说,甲状腺激素合成障碍表现为典型的孟德尔隐性遗传。CH极少起源于中枢,是下丘脑和/或垂体疾病的结果,导致促甲状腺激素释放激素(TRH)或促甲状腺激素(TSH)分泌减少或功能异常[10]。欲全面了解内分泌学的这一领域及所有相关领域,请访问我们的免费在线网络教科书:www.endotext.org。